From a strategic standpoint, the Sandostatin market remains highly attractive, driven by robust prevalence of neuroendocrine tumors and expanding indications in acromegaly management. Competitive intensity is moderate; while Octreotide remains the dominant product, emerging biosimilars and peptide‑based analogues are beginning to erode market share, prompting incumbents to reinforce pricing and patient‑support programs. The long‑term outlook is positive, with CAGR projected above 5% through 2032 as diagnostic penetration improves and guideline endorsements broaden usage. Innovation is focused on next‑generation depot formulations, oral delivery platforms, and combination regimens that aim to enhance adherence and reduce infusion burden. Demand‑supply balance is currently stable, but scaling of biosimilar capacity could tighten inventories and pressure pricing if demand outpaces production ramp‑up. Key risk factors include regulatory delays for new indications, reimbursement tightening in major markets, and potential safety signals from long‑term exposure. Overall, the Sandostatin market outlook suggests sustained growth for players that can navigate competitive pressure while capitalising on pipeline advances.
